SCHEMBL6897071

SCHEMBL6897071

O=Cc1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.81
ALDH5A1 P51649 1/20 0.63
ABAT P80404 1/20 0.63
GPR35 Q9HC97 4/20 0.57
ERN1 O75460 1/20 0.55
VCAM1 P19320 1/20 0.53
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
RECQL P46063 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL346035 0.90 XDH (1.00) XDHALDH5A1ABATGPR35MEN1
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL29357099 0.90 XDH (1.00) XDHALDH5A1ABATGPR35MEN1
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL8731720 0.88 XDH (0.96) XDHALDH5A1ABATGPR35MEN1
SCHEMBL15783651 0.88 XDH (0.71) XDHALDH5A1ABATERN1
SCHEMBL4009103 0.87 XDH (0.69) XDHALDH5A1ABATGPR35ERN1
SCHEMBL532580 0.87 XDH (0.74) XDHALDH5A1ABATGPR35ERN1
SCHEMBL531545 0.87 XDH (0.69) XDHALDH5A1ABATGPR35ERN1
SCHEMBL2512695 0.87 XDH (0.69) XDHALDH5A1ABATGPR35ERN1
3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL28213417 0.87 XDH (0.93) XDHALDH5A1ABATGPR35MEN1
SCHEMBL531803 0.87 XDH (0.69) XDHALDH5A1ABATGPR35ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390336-A1 METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) 2004-02-25 EP claimed
WO-2002096849-A1 METHOD FOR PRODUCING AROMATIC ALDEHYDES AND KETONES BY THE CATALYTIC OXIDATION OF ALKYL-AROMATIC COMPOUNDS DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) 2002-12-05 WO claimed
US-9622988-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-04-18 US disclosed
US-9622988-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-04-18 US disclosed
US-20170099837-A1 EXTRACTS OF AGRICULTURAL HUSKS USED TO MODIFY THE METABOLISM OF PLANTS MEDINA ESQUER LUIS ROMAN (MX) 2017-04-13 US disclosed
US-9610257-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-04-04 US disclosed
US-9610257-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-04-04 US disclosed
US-9585848-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-03-07 US disclosed
US-9585848-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-03-07 US disclosed
US-9585847-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-03-07 US disclosed
US-9585847-B2 Small molecule xanthine oxidase inhibitors and methods of use BAYLOR COLLEGE OF MEDICINE (US) 2017-03-07 US disclosed
EP-1003721-A1 BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES GLAXO GROUP LIMITED (GB) 2000-05-31 EP disclosed
EP-0440324-B1 Substituted beta-diketones and their use in the treatment of inflammatory bowel disease ORION YHTYMAE OY (FI) 2000-04-12 EP disclosed
WO-1999010325-A1 BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES GLAXO GROUP LIMITED (GB) 1999-03-04 WO disclosed
US-5292771-A Treating inflammatory bowel disease ORION-YHTYMA OY (FI) 1994-03-08 US disclosed
US-5185370-A Substituted β-diketones and their use ORION-YHTYMA OY (FI) 1993-02-09 US disclosed
EP-0440324-A2 Substituted beta-diketones and their use ORION-YHTYMÀ„ OY (FI) 1991-08-07 EP disclosed
US-4192670-A HERBICIDES ELI LILLY AND COMPANY (US) 1980-03-11 US disclosed
US-4122184-A Benzimidazole insecticides ELI LILLY AND COMPANY (US) 1978-10-24 US disclosed
US-4054439-A HERBICIDES ELI LILLY AND COMPANY (US) 1977-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170099837-A1 EXTRACTS OF AGRICULTURAL HUSKS USED TO MODIFY THE METABOLISM OF PLANTS PCK1, SNRK, HPD XDH 1525/4885ALDH5A1 1222/4885ABAT 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.